Theratechnologies (NASDAQ:THTX) Stock Price Up 0.5% - Still a Buy?

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report)'s stock price shot up 0.5% on Wednesday . The stock traded as high as $2.78 and last traded at $2.76. 383,922 shares traded hands during trading, a decline of 52% from the average session volume of 799,915 shares. The stock had previously closed at $2.74.

Analyst Upgrades and Downgrades

THTX has been the topic of a number of recent analyst reports. Jones Trading raised shares of Theratechnologies from a "hold" rating to a "strong-buy" rating in a research report on Friday, April 11th. Research Capitl upgraded Theratechnologies to a "strong-buy" rating in a research report on Friday, February 14th.

Theratechnologies Stock Up 1.1%

The company has a market cap of $121.39 million, a price-to-earnings ratio of -26.40 and a beta of 0.56. The firm has a 50-day simple moving average of $2.03 and a 200 day simple moving average of $1.73.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new position in Theratechnologies in the 4th quarter valued at about $27,000. Bank of America Corp DE increased its holdings in shares of Theratechnologies by 1,416.7% in the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock valued at $30,000 after purchasing an additional 15,400 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Theratechnologies during the fourth quarter worth approximately $33,000. BNP Paribas Financial Markets purchased a new position in Theratechnologies in the 4th quarter valued at $36,000. Finally, Virtu Financial LLC acquired a new position in Theratechnologies in the 4th quarter valued at $40,000.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.